Sanofi (FR:SAN)
:SAN
Want to see FR:SAN full AI Analyst Report?
SAN Stock Chart & Stats
€82.02
€0.05(0.05%)
At close: 4:00 PM EST
€82.02
€0.05(0.05%)
Day’s Range― - ―
52-Week Range€71.73 - €91.15
Previous CloseN/A
Volume78.83K
Average Volume (3M)1.95M
Market Cap
€92.01B
Enterprise Value€104.99B
Total Cash (Recent Filing)€7.66B
Total Debt (Recent Filing)€21.80B
Price to Earnings (P/E)8.9
Beta0.77
Next Earnings
Jul 30, 2026EPS Estimate
1.9Next Dividend Ex-DateN/A
Dividend Yield4.77%
Share Statistics
EPS (TTM)4.19
Shares Outstanding1,214,098,600
10 Day Avg. Volume1,590,247
30 Day Avg. Volume1,950,864
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.31
P/FCF Ratio11.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€95.22Price Target Upside16.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)8.51
Revenue Forecast (FY)€48.77B
Bulls Say, Bears Say
Bulls Say
Gross And Operating ProfitabilitySanofi’s sustained high gross margins and an improving net margin reflect durable operating leverage from biologics and vaccines. Strong margins support R&D, commercial investment and dividend capacity, helping the firm absorb revenue cyclicality and fund long-term pipeline development.
Conservative Balance Sheet And Moderate LeverageModerate leverage provides financial flexibility to fund M&A, sustain R&D and weather product cycles. A conservatively positioned balance sheet reduces refinancing risk, enabling multi-year investments in manufacturing and pipelines without immediate pressure to cut capex or R&D.
Strong Commercial Momentum And Regulatory ProgressRobust sales growth driven by launches, acquisitions and Dupixent’s large franchise expands durable revenue streams. Multiple approvals and positive trial readouts broaden indications, improving long-term addressable market and supporting sustainable top-line and EPS growth over coming quarters.
Bears Say
2025 Revenue ContractionA notable revenue decline signals product lifecycle pressures or portfolio shortfalls that can persist absent new launches. Reduced scale can depress sales-driven operating leverage, requiring sustained product or commercial fixes to restore multi-period top-line growth.
Weakening Free Cash Flow ConversionA sharp drop in free cash flow despite positive net income reduces internal funding for R&D, manufacturing and dividends. Weaker cash conversion over multiple years can force higher external financing, slow buybacks or constrain discretionary investments vital for long-term pipeline commercialization.
Regulatory And Political Scrutiny Of VaccinesHeightened political and regulatory scrutiny of vaccines and turnover at regulators increases risk to tender volumes, approval timelines and public vaccination programs. For a major vaccines manufacturer, sustained policy uncertainty can materially affect procurement contracts and long-term demand.
Sanofi News
SAN FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €71.73 and its highest was €91.15 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is €92.01B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Jul 30, 2026 which is in 47 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Apr 23, 2026. The company reported €1.88 earnings per share for the quarter, beating the consensus estimate of €1.789 by €0.091.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of €4.12 which represents an annual dividend yield of 4.77%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.9.
How many shares outstanding does Sanofi have?
Sanofi has 1,214,098,600 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €1.88 in its last earnings report, beating expectations of €1.789. Following the earnings report the stock price went up 1.213%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in FR:SAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
SAN Company Deck
SAN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong financial and commercial execution in 2025, with robust top-line growth, margin expansion, cash generation, multiple high-impact product launches, and extensive pipeline progress and regulatory approvals. Notable challenges include a Phase III failure (tolebrutinib for PPMS), a safety signal (single Kaposi sarcoma case) requiring monitoring, reductions in Regeneron R&D reimbursement with medium-term BOI implications, and uncertainty in the vaccine market driven by recent U.S. schedule changes. On balance, the company’s positive financial results, successful launches, active BD/investment strategy, and constructive pipeline readouts outweigh the material but manageable challenges.View all FR:SAN earnings summariesSAN Stock 12 Month Forecast
Average Price Target
€95.22
▲(16.10% Upside)
Technical Analysis
Options Prices
Currently, No data available
---